Patient Guide: First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 14 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06351592
Status: 🟢 Enrolling Now
Condition: Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene
Phase: PHASE1

Where You Can Participate

This study is available at 14 locations across the country.

Top locations include:
  • • Concord, New South Wales
  • • Sydney, New South Wales
  • • Birtinya, Queensland
  • • And 11 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS) - Join Clinical Trial NCTNCT06351592

How to Join This Clinical Trial - NCTNCT06351592

Learn how to participate in this PHASE1 trial studying an investigational therapy for Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene
Treatment Being Tested
Investigational treatment
Study Phase
PHASE1 - Early safety study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06351592 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 14 locations. Find a study site near you:

Clinical Research Site

Concord, New South Wales 2139 - Australia

Status: RECRUITING

Clinical Research Site

Sydney, New South Wales 2109 - Australia

Status: RECRUITING

Clinical Research Site

Birtinya, Queensland 4575 - Australia

Status: RECRUITING

Clinical Research Site

Edmonton, Alberta T6G 2G3 - Canada

Status: RECRUITING

Clinical Research Site

London, Ontario N6A 5A5 - Canada

Status: RECRUITING

Clinical Research Site

Toronto, Ontario M4N3M5 - Canada

Status: RECRUITING

Clinical Research Site

Montreal, Quebec H3A 2B4 - Canada

Status: RECRUITING

Clinical Research Site

Sapporo, Hokkaido 060-8648 - Japan

Status: RECRUITING

Clinical Research Site

Tokushima, Tokushima 770-0042 - Japan

Status: RECRUITING

Clinical Research Site

Ōta-ku, Tokyo 143-8541 - Japan

Status: RECRUITING

And 4 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE1 clinical trial for Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships